To all the long-longs out there, we have to hold tight on this deal. Trius has just begun to attract the attention of the larger market and the gains of the past few months are only the beginning. Voting yes on this low ball deal is essentially agreeing to give up all the gains we were expecting around the NDA and PDUFA events.
Levi & Korsinsky is investigating the Board of Directors of Trius Therapeutics, Inc. (“Trius” or the “Company”) (TSRX) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cubist Pharmaceuticals, Inc. (CBST).
Contact this law firm at the email address provided in the Business Wire article to express your support. If they can block or delay the deal, gives more time for Pfizer or others to counter offer.
Greed is a relative thing. It appears that Cubist is more greedy than all of us and is scooping up the prize and leaving us with a portion of our expected gains.
So... not greedy, simply demanding a fairer offer.